290 related articles for article (PubMed ID: 34517192)
41. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
Shmidt TE
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
[TBL] [Abstract][Full Text] [Related]
42. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
43. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States.
Kern DM; Cepeda MS
BMC Neurol; 2020 Aug; 20(1):296. PubMed ID: 32781983
[TBL] [Abstract][Full Text] [Related]
44. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
Salavisa M; Serrazina F; Ladeira AF; Correia AS
Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
[TBL] [Abstract][Full Text] [Related]
45. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
46. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
Pasca M; Forci B; Mariottini A; Mechi C; Barilaro A; Massacesi L; Repice AM
Mult Scler Relat Disord; 2021 Jan; 47():102591. PubMed ID: 33142245
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
48. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
49. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
50. Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis.
Coerver EME; Bourass A; Wessels MHJ; van Kempen ZLE; Jasperse MMS; Tonino BAR; Barkhof F; Mostert J; Uitdehaag BMJ; Killestein J; Strijbis EMM
Mult Scler Relat Disord; 2023 Jun; 74():104706. PubMed ID: 37068370
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C
Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667
[TBL] [Abstract][Full Text] [Related]
52. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.
Sałacińska D; Pogoda A; Żółkiewicz J; Stępień A
Pol Merkur Lekarski; 2019 Dec; 47(282):221-225. PubMed ID: 31945023
[TBL] [Abstract][Full Text] [Related]
54. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
55. Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.
Granqvist M; Burman J; Gunnarsson M; Lycke J; Nilsson P; Olsson T; Sundström P; Svenningsson A; Vrethem M; Frisell T; Piehl F
Mult Scler; 2020 Oct; 26(12):1532-1539. PubMed ID: 31392923
[TBL] [Abstract][Full Text] [Related]
56. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
57. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
58. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
Lanzillo R; Prosperini L; Gasperini C; Moccia M; Fantozzi R; Tortorella C; Nociti V; Annovazzi P; Cavalla P; Radaelli M; Malucchi S; Clerici VT; Boffa L; Buttari F; Ragonese P; Maniscalco GT; Di Filippo M; Buscarinu MC; Pinardi F; Gallo A; Coghe G; Pesci I; Laroni A; Gajofatto A; Calabrese M; Tomassini V; Cocco E; Solaro C;
J Neurol; 2018 May; 265(5):1174-1183. PubMed ID: 29549468
[TBL] [Abstract][Full Text] [Related]
59. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
60. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
